Bounded definition
The cited GUIDE-seq workflow uses targeted sequencing and validation to characterize nominated cleavage sites under specified experiments. Within this page, that proposition is limited to The constructs, biological systems, protocols, assays, datasets, and comparisons reported in GUIDE-seq enables genome-wide profiling of off-target cleavage by CRISPR-Cas nucleases.
Definition and evidence boundary
Locus-focused sequencing used to quantify intended edits, indels, and selected nominated off-target outcomes. The bounded proposition retained by the canonical record is: The cited GUIDE-seq workflow uses targeted sequencing and validation to characterize nominated cleavage sites under specified experiments.
The applicable scope is The constructs, biological systems, protocols, assays, datasets, and comparisons reported in GUIDE-seq enables genome-wide profiling of off-target cleavage by CRISPR-Cas nucleases. This definition must not be generalized beyond the cited source and exact record boundary.
Claims: urn:maha:claim:targeted-amplicon-sequencing
Mechanism and technical context
The study develops GUIDE-seq, a cell-based double-strand-break capture method, and applies it to specified nucleases and human cell lines. This is the source-bound technical context for the record; no uncited mechanism is added by the compiler.
Amplicon assays are limited by primer design, sampled sites, allele representation, read depth, error correction, and variant-calling thresholds. The mechanism or method is therefore presented as one component of a larger system, not as evidence for every downstream outcome.
Claims: urn:maha:claim:targeted-amplicon-sequencing
How to interpret the evidence
There is no universal effect estimate for this method; numerical results remain attached to the source experiment, biological system, assay, and analysis choices. The evidence maturity recorded here is single study, and the claim kind is empirical claim.
This candidate records one bounded source package. Independent replications and contradictory results must be compiled separately before evidence maturity is upgraded. GUIDE-seq has assay-specific detection limits and dependencies and does not nominate every possible off-target event in every biological context. These qualifications travel with the claim whenever it is reused.
Claims: urn:maha:claim:targeted-amplicon-sequencing
What the source supports and what remains unknown
The inspected source supports exactly this: The study develops GUIDE-seq, a cell-based double-strand-break capture method, and applies it to specified nucleases and human cell lines. It was read at Abstract; Figures 1–6; Online Methods; Supplementary Tables; Sequence Read Archive SRP050338.
What remains unknown is everything outside that locator. Amplicon assays are limited by primer design, sampled sites, allele representation, read depth, error correction, and variant-calling thresholds. No quantity, comparison, or downstream outcome is established here unless a separately scoped record measures it.
Claims: urn:maha:claim:targeted-amplicon-sequencing
Source identity, locator, and reuse boundary
The bound source is “GUIDE-seq enables genome-wide profiling of off-target cleavage by CRISPR-Cas nucleases” by Shengdar Q. Tsai, Zongli Zheng, Nhu T. Nguyen, Matthew Liebers, et al., published by Nature Biotechnology on 2014-12-16; its declared stable identity is doi:10.1038/nbt.3117.
The inspected-content locator is Abstract; Figures 1–6; Online Methods; Supplementary Tables; Sequence Read Archive SRP050338. Reuse is limited to citation-with-paraphrase. Maha paraphrases the source-level result and links to the version of record; no article passage is reproduced. This metadata establishes source identity and inspection scope, not the truth of claims outside the cited locator.
Claims: urn:maha:claim:targeted-amplicon-sequencing
Comparison and calculation boundary
Applicability is decided explicitly, not filled with generic material.
This record carries 1 source-bound proposition and therefore has no second supported side. A comparison would have to be manufactured from an adjacent title rather than from a second inspected claim, which the gate forbids.
The canonical claim declares no reproducible numerical inputs, equation, units, or uncertainty propagation; recorded uncertainty kind is qualitative. Supplying sample values would invent an unsupported quantitative result.
Limitations and prohibited inference
The claim stops where its evidence stops.
- record boundary
Amplicon assays are limited by primer design, sampled sites, allele representation, read depth, error correction, and variant-calling thresholds.
- record boundary
A source-bounded mechanism, method, or measurement record does not establish manufacturing yield, economic advantage, safety, clinical benefit, or commercial readiness unless those outcomes are measured in a separately scoped record.
- prohibited inference
Do not treat the targeted amplicon sequencing of edit outcomes record as medical advice, a treatment recommendation, or evidence of general clinical readiness.
- prohibited inference
Do not transfer a reported result across hardware, organisms, protocols, datasets, operating conditions, or outcome definitions without a declared comparison contract.
- editorial
This compilation reorganizes an existing inspected claim and its declared source; it does not add a new experiment, measurement, or independent replication.
- editorial
Internal editorial inspection is not external peer review, and no result on this page has been independently reproduced.
Related records and mathematical bridges
Typed links expose context without asserting equivalence.
Adenine base editing
Same canonical domain (synthetic-biology). Domain membership only: no shared source or declared edge links these two records.
Selection: domain adjacency
Editing efficiency and byproduct measurement
Declared mechanistic-dependency edge from this record. The edge is navigational and asserts no equivalence or causation beyond the cited source scope.
Selection: bridge edge
GUIDE-seq off-target detection
Cites the same source as this record, so the two are related through the evidence rather than through wording.
Selection: shared source
When no declared bridge edge is present, related records are linked by shared evidence or canonical domain adjacency. Those links are navigational and do not claim mathematical or physical equivalence.
Connected domain graph
Typed dependencies preserve publication state.
Only independently canonical records receive public links and relation statements. Draft graph topology remains private.
Editing efficiency and byproduct measurement
outbound connection · measurement
Targeted sequencing supplies one measurement channel for intended products and local byproducts.
Editing efficiency and byproduct measurement
inbound connection · measurement
Targeted sequencing is one method used to resolve the product distribution.
Claim ledger
Every proposition keeps its own evidence state.
The cited GUIDE-seq workflow uses targeted sequencing and validation to characterize nominated cleavage sites under specified experiments.
- Scope
- The constructs, biological systems, protocols, assays, datasets, and comparisons reported in GUIDE-seq enables genome-wide profiling of off-target cleavage by CRISPR-Cas nucleases.
- Boundary
- Amplicon assays are limited by primer design, sampled sites, allele representation, read depth, error correction, and variant-calling thresholds.
- Uncertainty
- There is no universal effect estimate for this method; numerical results remain attached to the source experiment, biological system, assay, and analysis choices.
- Replication
- This candidate records one bounded source package. Independent replications and contradictory results must be compiled separately before evidence maturity is upgraded.
Primary sources
Citation, locator, rights, and boundary travel together.
Source 1 · Nature Biotechnology
GUIDE-seq enables genome-wide profiling of off-target cleavage by CRISPR-Cas nucleases
Shengdar Q. Tsai, Zongli Zheng, Nhu T. Nguyen, Matthew Liebers, et al.
- Exact locator
- Abstract; Figures 1–6; Online Methods; Supplementary Tables; Sequence Read Archive SRP050338.
- Establishes
- The study develops GUIDE-seq, a cell-based double-strand-break capture method, and applies it to specified nucleases and human cell lines.
- Boundary
- GUIDE-seq has assay-specific detection limits and dependencies and does not nominate every possible off-target event in every biological context.
- Rights basis
- citation with paraphrase · Maha paraphrases the source-level result and links to the version of record; no article passage is reproduced.